ZEVRA THERAPEUTICS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

ZEVRA THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $62.41 million for the year ending 2025.

  • ZEVRA THERAPEUTICS, INC. showed an increase of +84.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from ZEVRA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2014: $1.06 million | Q2 2014: $22.96 million | Q3 2014: $19.02 million | Q1 2015: $10.27 million | Q2 2015: $64.22 million | Q3 2015: $59.01 million | Q4 2015: $32.32 million | Q1 2016: $77.33 million | Q2 2016: $27.51 million | Q3 2016: $20.85 million | Q1 2017: $12.88 million | Q2 2017: $12.39 million | Q3 2017: $7.83 million | Q1 2018: $8.75 million | Q2 2018: $16.50 million | Q3 2018: $1.79 million | Q1 2019: $13.44 million | Q2 2019: $7.31 million | Q3 2019: $6.52 million | Q1 2020: $2.36 million | Q2 2020: $6.37 million | Q3 2020: $5.27 million | Q1 2021: $75.92 million | Q2 2021: $132.30 million | Q3 2021: $131.50 million | Q1 2022: $100.24 million | Q2 2022: $76.78 million | Q3 2022: $70.06 million | Q1 2023: $40.18 million | Q2 2023: $66.20 million | Q3 2023: $43.27 million | Q1 2024: $42.85 million | Q2 2024: $39.26 million | Q3 2024: $54.04 million | Q1 2025: $37.34 million | Q2 2025: $47.71 million | Q3 2025: $54.44 million.
  • Over the full 14 years of available data (2012 to 2025), ZEVRA THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,355.0%.
  • Historical annual values: Fiscal year 2025: $62.41 million | Fiscal year 2024: $33.79 million | Fiscal year 2023: $43.05 million | Fiscal year 2022: $65.47 million | Fiscal year 2021: $112.35 million | Fiscal year 2020: $4.21 million | Fiscal year 2019: $3.22 million | Fiscal year 2018: $18.41 million | Fiscal year 2017: $10.87 million | Fiscal year 2016: $16.76 million | Fiscal year 2015: $32.32 million | Fiscal year 2014: $10.26 million | Fiscal year 2013: $1.97 million | Fiscal year 2012: $2.54 million.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: